Identification

Name
Indomethacin
Accession Number
DB00328  (APRD00109)
Type
Small Molecule
Groups
Approved, Investigational
Description

Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.

Structure
Thumb
Synonyms
  • {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
  • 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
  • Aconip
  • Indometacin
  • Indometacina
  • Indometacine
  • Indometacinum
  • Indomethacin
External IDs
NSC-77541
Product Ingredients
IngredientUNIICASInChI Key
Indomethacin sodium0IMX38M2GG74252-25-8UHYAQBLOGVNWNT-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Indomethacin Cap 25mgCapsule25 mgOralApotex Corporation1984-12-31Not applicableCanada
Apo Indomethacin Cap 50mgCapsule50 mgOralApotex Corporation1984-12-31Not applicableCanada
Indocid Cap 25mgCapsule25 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1965-12-311998-08-14Canada
Indocid Cap 50mgCapsule50 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1970-12-311998-08-14Canada
Indocid SR 75mgCapsule, extended release75 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1980-12-311999-08-06Canada
Indocid Sterile Oph Susp 1%Solution / drops10 mgOphthalmicMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-311999-08-06Canada
Indocid Sup 100mgSuppository100 mgRectalMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1971-12-312003-08-08Canada
Indocid Sup 50mgSuppository50 mgRectalMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-312003-08-08Canada
IndocinSuspension25 mg/5mLOralIroko Pharmaceuticals, LLC1985-10-10Not applicableUs
IndocollyreLiquid; Powder, for solution1 mgOphthalmicLaboratoire Chauvin S.A.1997-02-132001-01-19Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ftp-indomethacinCapsule50 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-indomethacinCapsule25 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
IndocinSuppository50 mg/1RectalIroko Pharmaceuticals, LLC1992-08-31Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralPaddock Laboratories, Inc.2010-11-302016-12-31Us
IndomethacinCapsule50 mg/1OralA S Medication Solutions2011-11-012017-06-20Us
IndomethacinCapsule50 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1984-04-20Not applicableUs
IndomethacinCapsule25 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-16Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralActavis Pharma Company2013-12-172017-07-19Us
IndomethacinCapsule25 mg/1OralRemedy Repack2010-12-062016-10-13Us00093 4029 01 nlmimage10 272713c8
IndomethacinCapsule50 mg/1OralRed Pharm Drug, Inc.2007-04-01Not applicableUs
International/Other Brands
Arthrexin (Alphapharm) / Elmetacin (Sankyo) / Indaflex (Andromaco) / Indocid (Lundbeck) / Indocin / Indolar SR (Sandoz) / Indomed (Greater Pharma) / Indoxen (Quality Pharmaceutical) / Metindol (GlaxoSmithKline) / Mikametan (Mikasa Seiyaku) / Nu-Indo (Nu-Pharm) / Reumacide (Vitória)
Categories
UNII
XXE1CET956
CAS number
53-86-1
Weight
Average: 357.788
Monoisotopic: 357.076785712
Chemical Formula
C19H16ClNO4
InChI Key
CGIGDMFJXJATDK-UHFFFAOYSA-N
InChI
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
IUPAC Name
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
SMILES
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O

Pharmacology

Indication

For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

Structured Indications
Pharmacodynamics

Indomethacin, a NSAIA, with analgesic and antipyretic properties exerts its pharmacological effects by inhibiting the synthesis of prostaglandins involved in pain, fever, and inflammation. Indomethacin inhibits the catalytic activity of the COX enzymes, the enzymes responsible for catalyzing the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. Indomethacin is known to inhibit two well-characterized isoforms of COX, COX-1 and COX-2, with greater selectivity for COX-1. COX-1 is a constitutively expressed enzyme that is involved in gastric mucosal protection, platelet and kidney function. It catalyzes the conversion of arachidonic acid to prostaglandin (PG) G2 and PGG2 to PGH2. COX-1 is involved in the synthesis pathways of PGE2, PGD2, PDF2a, PGI2 (also known as prostacyclin) and thromboxane A2 (TXA2). COX-2 is constitutively expressed and highly inducible by inflammatory stimuli. It is found in the central nervous system, kidneys, uterus and other organs. It also catalyzes the conversion of arachidonic acid to PGG2 and PGG2 to PGH2. In the COX-2-mediated pathway, PGH2 is subsequently converted to PGE2 and PGI2 (also known as prostacyclin). PGE2 is involved in mediating inflammation, pain and fever. Decreasing levels of PGE2 leads to decreased inflammation.

Mechanism of action

Indomethacin is a prostaglandin G/H synthase (also known as cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. Indomethacin antagonizes COX by binding to the upper portion of the active site, preventing its substrate, arachidonic acid, from entering the active site. Indomethacin, unlike other NSAIDs, also inhibits phospholipase A2, the enzyme responsible for releasing arachidonic acid from phospholipids. Indomethacin is more selective for COX-1 than COX-2, which accounts for its increased adverse gastric effects relative to other NSAIDs. COX-1 is required for maintaining the protective gastric mucosal layer. The analgesic, antipyretic and anti-inflammatory effects of indomethacin occur as a result of decreased prostaglandin synthesis. Its antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

TargetActionsOrganism
UProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
APhospholipase A2, membrane associated
inhibitor
Human
UProstaglandin reductase 2
inhibitor
Human
UPeroxisome proliferator-activated receptor gamma
activator
Human
ULactoylglutathione lyase
inhibitor
Human
UProstaglandin D2 receptor 2
other/unknown
Human
UPeroxisome proliferator-activated receptor alpha
agonist
Human
UAldo-keto reductase family 1 member C3
inhibitor
Human
Absorption

Bioavailability is approximately 100% following oral administration and 80–90% following rectal administration.

Volume of distribution
Not Available
Protein binding

97%

Metabolism

Hepatic.

Route of elimination

Indomethacin is eliminated via renal excretion, metabolism, and biliary excretion.

Half life

4.5 hours

Clearance
Not Available
Toxicity

The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD50 of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Indomethacin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Indomethacin is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Indomethacin is combined with 5-androstenedione.Experimental, Illicit
AbciximabIndomethacin may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Indomethacin can be decreased when combined with Abiraterone.Approved
AcebutololIndomethacin may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolIndomethacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetyl sulfisoxazoleThe metabolism of Indomethacin can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinIndomethacin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Indomethacin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Indomethacin.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Aldosterone.Experimental, Investigational
AldoxorubicinIndomethacin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.Approved
AliskirenIndomethacin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alminoprofen.Experimental
AlprenololIndomethacin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Indomethacin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Amcinonide.Approved
AmikacinIndomethacin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideIndomethacin may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Indomethacin can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinIndomethacin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodIndomethacin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Indomethacin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Indomethacin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Anisodamine.Investigational
AnnamycinIndomethacin may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.Approved, Investigational
Antithrombin III humanIndomethacin may increase the anticoagulant activities of Antithrombin III human.Approved
ApalutamideThe serum concentration of Indomethacin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanIndomethacin may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Indomethacin is combined with Apocynin.Investigational
ApramycinIndomethacin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Indomethacin can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinIndomethacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinIndomethacin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanIndomethacin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Indomethacin can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololIndomethacin may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Atamestane.Investigational
AtenololIndomethacin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azelastine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Indomethacin.Investigational
BalsalazideIndomethacin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminIndomethacin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololIndomethacin may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinIndomethacin may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indomethacin.Approved
BenorilateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Indomethacin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Betamethasone.Approved, Vet Approved
BetaxololIndomethacin may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Indomethacin.Approved, Investigational
BevantololIndomethacin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
BisoprololIndomethacin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinIndomethacin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololIndomethacin may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Indomethacin can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Indomethacin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indomethacin.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Indomethacin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bucillamine.Investigational
BucindololIndomethacin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bufexamac.Approved, Experimental
BufuralolIndomethacin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Indomethacin.Approved
BupranololIndomethacin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Indomethacin.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indomethacin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Indomethacin can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Captopril.Approved
CarbamazepineThe metabolism of Indomethacin can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Indomethacin is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indomethacin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololIndomethacin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolIndomethacin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.Approved, Investigational
CeliprololIndomethacin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Indomethacin can be increased when it is combined with Ceritinib.Approved
CertoparinIndomethacin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloramphenicolThe metabolism of Indomethacin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indomethacin.Approved
CholecalciferolThe metabolism of Indomethacin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Indomethacin.Approved, Investigational
CimetidineThe metabolism of Indomethacin can be decreased when combined with Cimetidine.Approved, Investigational
CinoxacinIndomethacin may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Indomethacin can be decreased when combined with Citalopram.Approved
Citric AcidIndomethacin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Indomethacin.Vet Approved
CloranololIndomethacin may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Indomethacin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Indomethacin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Indomethacin can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Indomethacin is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indomethacin.Experimental
CyclosporineIndomethacin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indomethacin.Approved
DabrafenibThe serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinIndomethacin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIndomethacin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIndomethacin may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinIndomethacin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Delapril.Experimental
DelavirdineThe metabolism of Indomethacin can be decreased when combined with Delavirdine.Approved
DesirudinIndomethacin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indomethacin.Approved, Investigational
DextranIndomethacin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinIndomethacin may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Indomethacin is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Indomethacin.Approved, Vet Approved
DicoumarolIndomethacin may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Indomethacin.Approved
DihydrostreptomycinIndomethacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Indomethacin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Indomethacin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Indomethacin.Approved
DosulepinThe metabolism of Indomethacin can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Indomethacin.Approved, Investigational
DoxorubicinIndomethacin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneIndomethacin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Indomethacin is combined with E-6201.Investigational
Edetic AcidIndomethacin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Indomethacin.Approved
EfavirenzThe metabolism of Indomethacin can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Indomethacin is combined with Enalaprilat.Approved
EnoxacinIndomethacin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinIndomethacin may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Indomethacin.Experimental
EpanololIndomethacin may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Indomethacin is combined with Epirizole.Approved
EpirubicinIndomethacin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Indomethacin.Experimental
EplerenoneIndomethacin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indomethacin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Indomethacin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Equilin.Approved
Eslicarbazepine acetateThe metabolism of Indomethacin can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololIndomethacin may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Indomethacin can be decreased when combined with Esomeprazole.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indomethacin.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Indomethacin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ethenzamide.Experimental
Ethyl biscoumacetateIndomethacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Indomethacin can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Evening primrose oil.Investigational, Nutraceutical
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Indomethacin.Approved
ExisulindThe risk or severity of adverse effects can be increased when Indomethacin is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Indomethacin.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Feprazone.Experimental
Ferulic acidIndomethacin may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indomethacin.Approved, Investigational
FleroxacinIndomethacin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Indomethacin.Approved, Withdrawn
FloxuridineThe metabolism of Indomethacin can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Indomethacin can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fludrocortisone.Approved, Investigational
FluindioneIndomethacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineIndomethacin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Indomethacin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Indomethacin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Indomethacin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Indomethacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Indomethacin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Indomethacin can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indomethacin.Approved, Nutraceutical, Vet Approved
FondaparinuxIndomethacin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumIndomethacin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Indomethacin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Indomethacin can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinIndomethacin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Indomethacin.Approved, Vet Approved
GabexateIndomethacin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinIndomethacin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinIndomethacin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Indomethacin.Approved, Withdrawn
GemfibrozilThe metabolism of Indomethacin can be decreased when combined with Gemfibrozil.Approved
GemifloxacinIndomethacin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinIndomethacin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinIndomethacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AIndomethacin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Glucagon recombinantThe therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.Approved
GPX-150Indomethacin may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinIndomethacin may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Indomethacin is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Indomethacin is combined with HE3286.Investigational
HeparinIndomethacin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Higenamine.Investigational
HydralazineIndomethacin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indomethacin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
Hygromycin BIndomethacin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Indomethacin is combined with Icatibant.Approved, Investigational
IdarubicinIndomethacin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxIndomethacin may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indomethacin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.Approved
IndenololIndomethacin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Indomethacin can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Indobufen.Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Indoprofen.Withdrawn
IrbesartanThe metabolism of Indomethacin can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Indomethacin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsepamicinIndomethacin may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoniazidThe metabolism of Indomethacin can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Indomethacin is combined with Istaroxime.Investigational
KanamycinIndomethacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Indomethacin can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Indomethacin.Approved
LabetalolIndomethacin may decrease the antihypertensive activities of Labetalol.Approved
LandiololIndomethacin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Indomethacin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Indomethacin.Approved
LeflunomideThe metabolism of Indomethacin can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinIndomethacin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanIndomethacin may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololIndomethacin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinIndomethacin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Indomethacin.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Indomethacin.Approved
LobeglitazoneThe metabolism of Indomethacin can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lonazolac.Experimental
LopinavirThe metabolism of Indomethacin can be increased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Indomethacin can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Loteprednol.Approved
LovastatinThe metabolism of Indomethacin can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Indomethacin.Approved, Investigational
LuliconazoleThe serum concentration of Indomethacin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Indomethacin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Indomethacin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Indomethacin can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indomethacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Indomethacin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mefenamic acid.Approved
MelagatranIndomethacin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.Approved, Vet Approved
MepindololIndomethacin may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineIndomethacin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Indomethacin is combined with Metamizole.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Indomethacin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololIndomethacin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.Approved
MetoprololIndomethacin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideIndomethacin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinIndomethacin may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Indomethacin can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Indomethacin.Approved, Experimental
MifepristoneThe serum concentration of Indomethacin can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indomethacin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Indomethacin can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Indomethacin can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indomethacin.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolic acid.Approved
NabiloneThe metabolism of Indomethacin can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.Approved
NadololIndomethacin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinIndomethacin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatIndomethacin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naftifine.Approved
Nalidixic AcidIndomethacin may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Indomethacin.Approved
NaproxenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Indomethacin is combined with NCX 1022.Investigational
NeamineIndomethacin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololIndomethacin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NelfinavirThe metabolism of Indomethacin can be decreased when combined with Nelfinavir.Approved
NemonoxacinIndomethacin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinIndomethacin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Indomethacin.Approved, Investigational
NetilmicinIndomethacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Indomethacin can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nitroaspirin.Investigational
NorfloxacinIndomethacin may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indomethacin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Olopatadine.Approved
OlsalazineIndomethacin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Indomethacin is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Indomethacin is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Indomethacin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Orgotein.Vet Approved
OtamixabanIndomethacin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.Approved
Oxolinic acidIndomethacin may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololIndomethacin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.Approved
PantoprazoleThe metabolism of Indomethacin can be decreased when combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Parecoxib.Approved
ParomomycinIndomethacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Parthenolide.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Indomethacin.Approved
PazufloxacinIndomethacin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinIndomethacin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololIndomethacin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateIndomethacin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateIndomethacin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Perindopril.Approved
PhenindioneIndomethacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Indomethacin can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonIndomethacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Indomethacin can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pimecrolimus.Approved, Investigational
PindololIndomethacin may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidIndomethacin may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinIndomethacin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Indomethacin.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pirfenidone.Approved, Investigational
Piromidic acidIndomethacin may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pirprofen.Experimental
PitolisantThe serum concentration of Indomethacin can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorIndomethacin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinIndomethacin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinIndomethacin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indomethacin.Approved
PractololIndomethacin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Indomethacin.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Indomethacin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Indomethacin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Propacetamol.Approved, Investigational
PropranololIndomethacin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Indomethacin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Indomethacin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Indomethacin.Vet Approved
Protein CIndomethacin may increase the anticoagulant activities of Protein C.Approved
Protein S humanIndomethacin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIndomethacin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Indomethacin.Approved
PrulifloxacinIndomethacin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Indomethacin is combined with PTC299.Investigational
PuromycinIndomethacin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Indomethacin can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indomethacin.Approved
QuinineThe metabolism of Indomethacin can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Indomethacin.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinIndomethacin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinIndomethacin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Indomethacin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Indomethacin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Indomethacin.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.Approved, Investigational
RivaroxabanIndomethacin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinIndomethacin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Indomethacin can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinIndomethacin may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinIndomethacin may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Indomethacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indomethacin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Indomethacin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Indomethacin.Approved, Investigational
SecobarbitalThe metabolism of Indomethacin can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Indomethacin is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Indomethacin is combined with Serrapeptase.Investigational
SertralineThe metabolism of Indomethacin can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Indomethacin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Indomethacin.Approved
SisomicinIndomethacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinIndomethacin may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Indomethacin.Approved
SorafenibThe metabolism of Indomethacin can be decreased when combined with Sorafenib.Approved, Investigational
SotalolIndomethacin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CIndomethacin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinIndomethacin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinIndomethacin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Spirapril.Approved
SpironolactoneIndomethacin may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Indomethacin is combined with SRT501.Investigational
StiripentolThe metabolism of Indomethacin can be decreased when combined with Stiripentol.Approved
StreptomycinIndomethacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinIndomethacin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfadiazineThe metabolism of Indomethacin can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Indomethacin can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Indomethacin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Sulindac.Approved, Investigational
SulodexideIndomethacin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Indomethacin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Suxibuzone.Experimental
TacrolimusIndomethacin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Indomethacin.Approved
TalinololIndomethacin may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Indomethacin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Indomethacin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indomethacin.Approved, Investigational
TemafloxacinIndomethacin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide.Approved
TertatololIndomethacin may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Indomethacin can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Indomethacin can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be increased when it is combined with Indomethacin.Approved, Investigational, Vet Approved
TimololIndomethacin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tixocortol.Approved, Withdrawn
TobramycinIndomethacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Indomethacin can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.Approved
TopiramateThe metabolism of Indomethacin can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Indomethacin can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Indomethacin.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Indomethacin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Indomethacin can be decreased when combined with Tranylcypromine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indomethacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneIndomethacin may increase the nephrotoxic activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indomethacin.Approved, Vet Approved
TrimethoprimThe metabolism of Indomethacin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Triptolide.Investigational
TrovafloxacinIndomethacin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinIndomethacin may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Indomethacin.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Indomethacin can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinIndomethacin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Indomethacin can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Indomethacin.Approved
VemurafenibThe serum concentration of Indomethacin can be increased when it is combined with Vemurafenib.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Indomethacin.Approved, Investigational
VoriconazoleThe metabolism of Indomethacin can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinIndomethacin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIndomethacin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Indomethacin can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinIndomethacin may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinIndomethacin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZucapsaicinThe metabolism of Indomethacin can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food or antacids to reduce irritation.

References

Synthesis Reference

Hubertus L. Regtop, John R. Biffin, "Preparation of divalent metal salts of indomethacin." U.S. Patent US5310936, issued November, 1917.

US5310936
General References
  1. Akbarpour F, Afrasiabi A, Vaziri ND: Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J. 1985 Jun;78(6):756-7. [PubMed:4002013]
  2. HART FD, BOARDMAN PL: INDOMETHACIN: A NEW NON-STEROID ANTI-INFLAMMATORY AGENT. Br Med J. 1963 Oct 19;2(5363):965-70. [PubMed:14056924]
  3. Lum GM, Aisenbrey GA, Dunn MJ, Berl T, Schrier RW, McDonald KM: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest. 1977 Jan;59(1):8-13. [PubMed:187624]
  4. Phelan KM, Mosholder AD, Lu S: Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003 Nov;64(11):1328-34. [PubMed:14658947]
  5. Ragheb M: The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990 Oct;10(5):350-4. [PubMed:2258452]
External Links
Human Metabolome Database
HMDB0014473
KEGG Drug
D00141
KEGG Compound
C01926
PubChem Compound
3715
PubChem Substance
46508291
ChemSpider
3584
BindingDB
17638
ChEBI
49662
ChEMBL
CHEMBL6
Therapeutic Targets Database
DAP000617
PharmGKB
PA449982
IUPHAR
1909
Guide to Pharmacology
GtP Drug Page
HET
IMN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Indomethacin
ATC Codes
S01CC02 — Indometacin and antiinfectivesM02AA23 — IndometacinM01AB01 — IndometacinM01AB51 — Indometacin, combinationsS01BC01 — IndometacinC01EB03 — Indometacin
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
PDB Entries
1s2a / 1z9h / 2bxk / 2bxm / 2bxq / 2dm6 / 2oth / 2zb8 / 3ads / 3adx
show 14 more
FDA label
Download (56.2 KB)
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentPremature Labour1
0RecruitingOtherCerebrovascular Circulation1
0Unknown StatusDiagnosticGastrointestinal Diseases1
1Active Not RecruitingTreatmentBreast Neoplasm, Male / Neoplasms, Breast / Triple Negative Breast Cancer (TNBC)1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedBasic ScienceAcute Gouty Arthritis1
1CompletedOtherNeoplasms, Colorectal / Neoplasms, Esophageal / Neoplasms, Ovarian1
1RecruitingBasic ScienceImpaired Small Intestinal Permeability1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
1, 2Active Not RecruitingTreatmentObstetric Labour, Premature1
1, 2CompletedBasic ScienceCardiovascular Disease (CVD) / High Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA) / Strokes1
1, 2RecruitingPreventionBrain Injury / Intraventricular Hemorrhage / Periventricular Leukomalacia / Renal Injury1
1, 2RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2TerminatedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Oral Cavity1
2CompletedPreventionPatent Ductus Arteriosus (PDA)1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentPreterm Labor With Intact Membranes1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingBasic ScienceAsthma Bronchial / Electrophilic Fatty Acids1
2RecruitingTreatmentCervical Squamous Cell Carcinoma In Situ / Vulvar High Grade Squamous Intraepithelial Lesion1
2RecruitingTreatmentPreterm Premature Rupture of Membranes1
2RecruitingTreatmentStage III Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma AJCC v7 / Stage III Prostate Cancer / Stage III Prostate Cancer AJCC v7 / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma AJCC v7 / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v71
2Unknown StatusDiagnosticElectroencephalography / Premature Births / Regional Blood Flow1
2Unknown StatusTreatmentPatent Ductus Arteriosus (PDA)1
2WithdrawnTreatmentAcute Gouty Arthritis1
2WithdrawnTreatmentPatent Ductus Arteriosus (PDA)1
2, 3RecruitingPreventionDifficult Embryo Transfer1
2, 3RecruitingPreventionPost-ERCP Pancreatitis1
2, 3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
2, 3TerminatedTreatmentPatent Ductus Arteriosus (PDA)1
3CompletedPreventionBleeding in the Brain / Intraventricular Hemorrhage (IVH) / Premature Babies / Very Low Birth Weight Infants1
3CompletedPreventionInfants, Premature / Patent Ductus Arteriosus (PDA) / Very Low Birth Weight Infant1
3CompletedPreventionPost-ERCP Acute Pancreatitis1
3CompletedTreatmentAcute Gout Flare1
3CompletedTreatmentAcute Gouty Arthritis1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAnkylosing Spondylitis (AS)1
3CompletedTreatmentCardiovascular Disease (CVD) / Defect, Congenital Heart / Heart Diseases / Patent Ductus Arteriosus (PDA)1
3CompletedTreatmentOther Acute Postoperative Pain2
3CompletedTreatmentPost ERCP Acute Pancreatitis1
3RecruitingTreatmentAcute Pancreatitis (AP)1
3TerminatedPreventionPost-ERCP Acute Pancreatitis1
3Unknown StatusTreatmentObstetric Labour, Premature1
3Unknown StatusTreatmentPain / Renal Colic1
4CompletedNot AvailablePatent Ductus Arteriosus (PDA) / Prematurity of Fetus1
4CompletedBasic ScienceHealthy Males / Neuromuscular Function2
4CompletedPreventionAcute Pancreatitis (AP)1
4CompletedPreventionCataracts / Inflammatory Reaction1
4CompletedPreventionFamily Planning1
4CompletedPreventionHealthy Volunteers1
4CompletedSupportive CareHemorrhage1
4CompletedTreatmentAnkle Sprains1
4CompletedTreatmentColorectal Cancers1
4CompletedTreatmentEnuresis1
4CompletedTreatmentMacular Edema (ME)1
4CompletedTreatmentPost-Operative Pain1
4Not Yet RecruitingTreatmentAcute Pancreatitis (AP)1
4Not Yet RecruitingTreatmentAcute Pancreatitis (AP) / Gastrointestinal Diseases1
4RecruitingPreventionPancreatitis1
4RecruitingTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis, Axial1
4RecruitingTreatmentPremature Labour1
4TerminatedPreventionPost-ERCP Pancreatitis1
4TerminatedPreventionPremature Labour1
4WithdrawnTreatmentPatent Ductus Arteriosus (PDA) / Very Low Birth Weight Infants1
Not AvailableActive Not RecruitingTreatmentObstetric Labour, Premature1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedPreventionPost-ERCP Acute Pancreatitis1
Not AvailableCompletedTreatmentCervical Insufficiency1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentNephrogenic Diabetes Insipidus1
Not AvailableCompletedTreatmentPancreatitis1
Not AvailableCompletedTreatmentPremature Labour1
Not AvailableRecruitingPreventionPancreatitis1
Not AvailableRecruitingTreatmentElbow Trauma Requiring Operative Management1
Not AvailableRecruitingTreatmentPatent Ductus Arteriosus (PDA)1
Not AvailableTerminatedPreventionEndoscopic Retrograde Cholangiopancreatography / Pancreatitis1
Not AvailableTerminatedTreatmentPatent Ductus Arteriosus (PDA) / Preterm Infants1
Not AvailableUnknown StatusNot AvailableLow Responders / Mild to Moderate Male Factor Infertility / Primary Infertility / Secondary Infertility1

Pharmacoeconomics

Manufacturers
  • Iroko pharmaceuticals llc
  • Sandoz inc
  • Able laboratories inc
  • Avanthi inc
  • Inwood laboratories inc sub forest laboratories inc
  • Teva pharmaceuticals usa inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Heritage pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Parke davis div warner lambert co
  • Pioneer pharmaceuticals inc
  • Pliva inc
  • Roxane laboratories inc
  • Superpharm corp
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • App pharmaceuticals llc
  • G and w laboratories inc
  • Lundbeck inc
  • Bedford laboratories div ben venue laboratories inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • Apothecary Shop Wholesale
  • A-S Medication Solutions LLC
  • Bedford Labs
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Central Texas Community Health Centers
  • Comprehensive Consultant Services Inc.
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Emcure Pharmaceuticals Ltd.
  • Endo Pharmaceuticals Inc.
  • Eon Labs
  • G & W Labs
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Inwood Labs
  • Iroko Pharmaceuticals
  • Kaiser Foundation Hospital
  • KVK-Tech Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Lundbeck Inc.
  • Major Pharmaceuticals
  • Medisca Inc.
  • Medvantx Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Talbert Medical Management Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Veratex Corp.
Dosage forms
FormRouteStrength
Capsule, extended releaseOral75 mg
Solution / dropsOphthalmic10 mg
SuppositoryRectal50 mg/1
SuspensionOral25 mg/5mL
Liquid; powder, for solutionOphthalmic1 mg
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral75 mg/1
Capsule, extended releaseOral75 mg/1
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
Injection, powder, lyophilized, for solutionIntravenous1 mg/1
CapsuleOral25 mg
CapsuleOral50 mg
SuppositoryRectal100 mg
SuppositoryRectal50 mg
CapsuleOral20 mg/1
CapsuleOral40 mg/1
Prices
Unit descriptionCostUnit
Indocin i.v. 1 mg vial642.6USD vial
Indomethacin 1 mg vial600.0USD vial
Indocin 50 mg suppository9.56USD suppository
Indomethacin CR 75 mg capsule3.12USD capsule
Indocin sr 75 mg capsule2.92USD capsule
Indomethacin powder2.57USD g
Ratio-Indomethacin 100 mg Suppository0.93USD suppository
Sandoz Indomethacin 100 mg Suppository0.93USD suppository
Sandoz Indomethacin 50 mg Suppository0.93USD suppository
Indomethacin 50 mg capsule0.65USD capsule
Indomethacin 25 mg capsule0.44USD capsule
Apo-Indomethacin 50 mg Capsule0.16USD capsule
Novo-Methacin 50 mg Capsule0.16USD capsule
Nu-Indo 50 mg Capsule0.16USD capsule
Apo-Indomethacin 25 mg Capsule0.09USD capsule
Novo-Methacin 25 mg Capsule0.09USD capsule
Nu-Indo 25 mg Capsule0.09USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9089471No2010-04-232030-04-23Us
US8992982No2010-04-232030-04-23Us
US8734847No2010-04-232030-04-23Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)151U.S. Patent 3,161,654.
water solubility0.937 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.27HANSCH,C ET AL. (1995)
logS-4.62ADME Research, USCD
Caco2 permeability-4.69ADME Research, USCD
pKa4.5BUDAVARI,S ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.0024 mg/mLALOGPS
logP4.25ALOGPS
logP3.53ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.8ChemAxon
pKa (Strongest Basic)-2.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity94.81 m3·mol-1ChemAxon
Polarizability36.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9509
Blood Brain Barrier+0.9381
Caco-2 permeable+0.5857
P-glycoprotein substrateNon-substrate0.636
P-glycoprotein inhibitor INon-inhibitor0.9313
P-glycoprotein inhibitor IINon-inhibitor0.834
Renal organic cation transporterNon-inhibitor0.8334
CYP450 2C9 substrateNon-substrate0.712
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6436
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9302
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6978
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8728
BiodegradationNot ready biodegradable0.9743
Rat acute toxicity4.0722 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Non-inhibitor0.8306
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.7 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-002f-9100000000-2545b33ef519ca9557d7
Mass Spectrum (Electron Ionization)MSsplash10-000i-1901000000-710010c41f0ded9b0f17
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0009000000-5a4abda1542473813a5d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0019000000-b80206e17a22fdf15299
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0093000000-4e04725a4a7ea8db1880
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0bt9-0906000000-44825d096b6f8c6091ab
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-053r-0890000000-e9f8e33084842b2a91e0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-5aee2869a858e70aa8cb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-5aee2869a858e70aa8cb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0019000000-b9916635c4db449698ab
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0092000000-270cd44f32c881ded6aa
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4j-0973000000-6e9ac766080e35c8b297
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-053r-0790000000-b0e6139fc1746c17ddb7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-1df95eb7ff5058a870cc
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0009000000-6a65e96ca253d6a3dda0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-08gi-0195000000-7ea82149ddaa783e01df
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-1208c0d5e605b8b69605
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4r-0709000000-1814b324e15b59fa31a5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-da84cf2df3db68610ae6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-f05d502a85960fefa1b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-ef4bc1155685673e5c96
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-f3d47b27b5deef302e24
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-529c521348d72ac3ac2c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4r-0709000000-552147af435f6203b275
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-3ecb36f2b39a0a31490e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-3f989b1435664e5bd1c9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-432dc50c7beda844e96f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-3a2c27afaa406477bb36
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-30707a04c6d14ccc1494
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-ceb3b04d9de59607c950
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-2902000000-8effecdaf737eb86e781
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0901000000-aa0cdbd9e10c432d837c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3900000000-353e94b605ae82792fae
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0901000000-5c9675c7c76c033ffc5b
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoylindoles. These are organic compounds containing an indole attached to a benzoyl moiety through the acyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Benzoylindoles
Direct Parent
Benzoylindoles
Alternative Parents
Indole-3-acetic acid derivatives / Indolecarboxylic acids and derivatives / 3-alkylindoles / 4-halobenzoic acids and derivatives / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Chlorobenzenes / Substituted pyrroles / Aryl chlorides
show 10 more
Substituents
Benzoylindole / Indole-3-acetic acid derivative / Indolecarboxylic acid derivative / Indolyl carboxylic acid derivative / 4-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / 3-alkylindole / Indole / Benzoic acid or derivatives / Anisole
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, monochlorobenzenes, N-acylindole, indole-3-acetic acids (CHEBI:49662) / a small molecule (CPD-10545)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Bobadilla L RA, Perez-Alvarez V, Bracho Valdes I, Lopez-Sanchez P: Effect of pregnancy on the roles of nitric oxide and prostaglandins in 5-hydroxytryptamine-induced contractions in rat isolated thoracic and abdominal aorta. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):202-9. [PubMed:15743404]
  2. Fornai M, Blandizzi C, Colucci R, Antonioli L, Bernardini N, Segnani C, Baragatti B, Barogi S, Berti P, Spisni R, Del Tacca M: Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May;54(5):608-16. [PubMed:15831902]
  3. Higuchi K, Tominaga K, Watanabe T, Uno H, Shiba M, Sasaki E, Tanigawa T, Takashima T, Hamaguchi M, Oshitani N, Matsumoto T, Iwanaga Y, Fukuda T, Fujiwara Y, Arakawa T: Indomethacin, but not Helicobacter pylori, inhibits adaptive relaxation in isolated guinea-pig stomach. Drugs Exp Clin Res. 2004;30(5-6):235-41. [PubMed:15700751]
  4. Kundu N, Walser TC, Ma X, Fulton AM: Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005 Oct;54(10):981-7. Epub 2005 May 13. [PubMed:15891886]
  5. Moth CW, Prusakiewicz JJ, Marnett LJ, Lybrand TP: Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1. J Med Chem. 2005 May 19;48(10):3613-20. [PubMed:15887968]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Armstrong PJ, Franklin DP, Carey DJ, Elmore JR: Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg. 2005 Mar;19(2):248-57. [PubMed:15770365]
  2. Jerde TJ, Calamon-Dixon JL, Bjorling DE, Nakada SY: Celecoxib inhibits ureteral contractility and prostanoid release. Urology. 2005 Jan;65(1):185-90. [PubMed:15667901]
  3. Pilane CM, Labelle EF: Nitric oxide stimulated vascular smooth muscle cells undergo apoptosis induced in part by arachidonic acid derived eicosanoids. J Cell Physiol. 2005 Aug;204(2):423-7. [PubMed:15668944]
  4. Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K: Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther. 2005 Jul;314(1):302-9. Epub 2005 Apr 14. [PubMed:15831440]
  5. Zhang GS, Fu YB, Xia M: [Proliferation inhibition effect of indomethacin on CML cells associated with down-regulation of phosphorylated STAT1/STAT5 and inhibition of COX-2 expression]. Zhonghua Xue Ye Xue Za Zhi. 2004 Dec;25(12):732-5. [PubMed:15730717]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Phospholipid binding
Specific Function
Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-ph...
Gene Name
PLA2G2A
Uniprot ID
P14555
Uniprot Name
Phospholipase A2, membrane associated
Molecular Weight
16082.525 Da
References
  1. Geisslinger, G., & Lötsch, J. (2004). Non-steroidal anti-inflammatory drugs. In Encyclopedic reference of molecular pharmacology (pp. 667-671). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
15-oxoprostaglandin 13-oxidase activity
Specific Function
Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-keto-PGE1, 15-keto-PGE2, 15-keto-PGE1-alpha and 15-keto-PGE2-alpha with highest activity towards 15-keto-PGE2. Overexpression represses...
Gene Name
PTGR2
Uniprot ID
Q8N8N7
Uniprot Name
Prostaglandin reductase 2
Molecular Weight
38498.74 Da
References
  1. Wu YH, Ko TP, Guo RT, Hu SM, Chuang LM, Wang AH: Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2. Structure. 2008 Nov 12;16(11):1714-23. doi: 10.1016/j.str.2008.09.007. [PubMed:19000823]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Cho MC, Lee HS, Kim JH, Choe YK, Hong JT, Paik SG, Yoon DY: A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma. J Biochem Mol Biol. 2003 Mar 31;36(2):207-13. [PubMed:12689521]
  2. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583]
Details
6. Lactoylglutathione lyase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF-kappa-B. Requ...
Gene Name
GLO1
Uniprot ID
Q04760
Uniprot Name
Lactoylglutathione lyase
Molecular Weight
20777.515 Da
References
  1. Sato S, Kwon Y, Kamisuki S, Srivastava N, Mao Q, Kawazoe Y, Uesugi M: Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. J Am Chem Soc. 2007 Jan 31;129(4):873-80. [PubMed:17243824]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Hata AN, Lybrand TP, Breyer RM: Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. J Biol Chem. 2005 Sep 16;280(37):32442-51. Epub 2005 Jul 19. [PubMed:16030019]
  2. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582]
  3. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kostenis E: Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Aug;68(2):393-402. Epub 2005 May 3. [PubMed:15870392]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2....
Gene Name
AKR1C3
Uniprot ID
P42330
Uniprot Name
Aldo-keto reductase family 1 member C3
Molecular Weight
36852.89 Da
References
  1. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, White SA: Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res. 2004 Mar 1;64(5):1802-10. [PubMed:14996743]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Mano Y, Usui T, Kamimura H: Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96. Epub 2007 Jan 24. [PubMed:17245571]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes. Biopharm Drug Dispos. 2005 Jan;26(1):35-9. [PubMed:15593333]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Mano Y, Usui T, Kamimura H: Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96. Epub 2007 Jan 24. [PubMed:17245571]
  2. Mano Y, Usui T, Kamimura H: Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol. 2007 Feb;63(2):211-6. Epub 2007 Jan 3. [PubMed:17200831]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. [PubMed:11581266]
  2. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890]
  3. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y: Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009 Feb;37(2):315-21. doi: 10.1124/dmd.108.024018. Epub 2008 Nov 24. [PubMed:19029202]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4...
Gene Name
ABCC6
Uniprot ID
O95255
Uniprot Name
Multidrug resistance-associated protein 6
Molecular Weight
164904.81 Da
References
  1. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674]
  3. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368]
  4. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
  5. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
  2. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  4. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087]
  5. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961]
  6. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364]
  7. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]
  8. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
  9. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  4. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
  5. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720]
  6. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798]
  2. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926]
  3. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  4. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Purine nucleotide transmembrane transporter activity
Specific Function
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a ...
Gene Name
ABCC11
Uniprot ID
Q96J66
Uniprot Name
ATP-binding cassette sub-family C member 11
Molecular Weight
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818]

Drug created on June 13, 2005 07:24 / Updated on May 22, 2018 23:40